Federal Policy
Trump Administration Claims All States Accepted GENEROUS Drug Pricing Model, Several States Deny Enrollment Decision
Trump administration officials announced that all states have agreed to participate in the GENEROUS model, a federal initiative designed to provide lower drug prices to state Medicaid programs. However, officials in multiple states say they have not committed to participation and are still evaluating whether GENEROUS offers better value than existing manufacturer rebate arrangements. Pricing details for the GENEROUS model remain unavailable to the public. The discrepancy raises questions about enrollment claims and creates uncertainty for state Medicaid agencies making coverage and financial planning decisions.
Why it mattersState Medicaid agencies face confusion about participation requirements and must assess financial impacts without transparent pricing data, complicating pharmacy benefit planning and budget forecasting.